Literature DB >> 1934246

Chemosensitivity and cytokine sensitivity of malignant mesothelioma.

R V Bowman1, L S Manning, M R Davis, B W Robinson.   

Abstract

Malignant mesothelioma arises in serosal tissues, is locally invasive, and is usually resistant to chemotherapeutic agents used clinically. To determine whether resistance to cytotoxic drugs was an inherent characteristic of mesothelioma cells, we performed in vitro chemosensitivity testing on five fully characterised human malignant mesothelioma cell lines and, for comparison, on three lines representative of clinically drug-resistant solid-tissue carcinomas using the MTT (tetrazolium bromide) assay system. Mesothelioma cell lines were intrinsically resistant to eight common antineoplastic drugs, with concentrations that produced a 50% reduction in optical density (IC50 values) for all drugs being equivalent, if not higher, for mesothelioma cell lines as compared with lung and colon carcinoma cell lines. We then investigated the direct anti-mesothelioma activity of recombinant human cytokines with their antineoplastic properties. All five mesothelioma cell lines were resistant to tumour necrosis factor, but they displayed varying degrees of sensitivity to interferons (IFNs). IFN gamma directly inhibited the growth of two of five mesothelioma lines. IFN alpha displayed little activity against four of five mesothelioma lines. The mesothelioma cells that were sensitive to IFN alpha were resistant to IFN gamma, indicating that sensitivity to IFNs is not a genetic characteristic of malignant mesothelioma cells. Significant interactions between cytokines in combination were not observed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1934246     DOI: 10.1007/bf00685817

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  26 in total

1.  Mortality in miners and millers of crocidolite in Western Australia.

Authors:  B K Armstrong; N H de Klerk; A W Musk; M S Hobbs
Journal:  Br J Ind Med       Date:  1988-01

2.  Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.

Authors:  M C Alley; D A Scudiero; A Monks; M L Hursey; M J Czerwinski; D L Fine; B J Abbott; J G Mayo; R H Shoemaker; M R Boyd
Journal:  Cancer Res       Date:  1988-02-01       Impact factor: 12.701

Review 3.  The pathogenesis of asbestos-associated diseases.

Authors:  J E Craighead; B T Mossman
Journal:  N Engl J Med       Date:  1982-06-17       Impact factor: 91.245

4.  Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers.

Authors:  A S Alberts; G Falkson; L Goedhals; D A Vorobiof; C A Van der Merwe
Journal:  J Clin Oncol       Date:  1988-03       Impact factor: 44.544

5.  Interaction between dactinomycin and tumor necrosis factor in mesothelioma. Cachexia without oncolysis.

Authors:  R V Bowman; D Whitaker; L S Manning; M R Davis; B W Robinson
Journal:  Cancer       Date:  1991-05-15       Impact factor: 6.860

6.  Expression of a multidrug resistance gene in human cancers.

Authors:  L J Goldstein; H Galski; A Fojo; M Willingham; S L Lai; A Gazdar; R Pirker; A Green; W Crist; G M Brodeur
Journal:  J Natl Cancer Inst       Date:  1989-01-18       Impact factor: 13.506

7.  Antiproliferative effects exerted by recombinant human tumor necrosis factor-alpha (TNF-alpha) and interferon-gamma (IFN-gamma) on human pancreatic tumor cell lines.

Authors:  W H Schmiegel; J Caesar; H Kalthoff; H Greten; H W Schreiber; H G Thiele
Journal:  Pancreas       Date:  1988       Impact factor: 3.327

8.  Malignant mesothelioma. The Eastern Cooperative Oncology Group (ECOG) experience.

Authors:  H J Lerner; D A Schoenfeld; A Martin; G Falkson; E Borden
Journal:  Cancer       Date:  1983-12-01       Impact factor: 6.860

9.  Recombinant leukocyte A interferon therapy for advanced hairy cell leukemia. Therapeutic and immunologic results.

Authors:  K A Foon; A E Maluish; P G Abrams; S Wrightington; H C Stevenson; A Alarif; M F Fer; W R Overton; M Poole; E F Schnipper
Journal:  Am J Med       Date:  1986-03       Impact factor: 4.965

10.  Extrapleural pneumonectomy for diffuse, malignant mesothelioma.

Authors:  M J DaValle; L P Faber; C F Kittle; R J Jensik
Journal:  Ann Thorac Surg       Date:  1986-12       Impact factor: 4.330

View more
  8 in total

1.  Treatment of a patient with malignant mesothelioma with interferon-alpha 2 based on in vitro sensitivity tests.

Authors:  V Sexl; L Wagner; M Wiesholzer; E Presterl; W Base
Journal:  Clin Investig       Date:  1994-03

2.  Ifosfamide, mesna, and interferon-alpha2A combination chemoimmunotherapy in malignant mesothelioma: results of a single center in central anatolia.

Authors:  Mustafa Altinbas; Ozlem Er; Metin Ozkan; Hasan Senol Coskun; Inci Gulmez; Eyup Ekici; Bunyamin Kaplan; Bulent Eser; Mustafa Ozesmi
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

3.  Successful immunochemotherapy for patients with malignant mesothelioma: report of two cases.

Authors:  M Tani; H Tanimura; H Yamaue; S Mizobata; M Yamamoto; M Iwahashi; K Ura; Y Nagai; T Tsunoda; H Wakasaki; K Nanjo; K Fujino; S Yukawa
Journal:  Surg Today       Date:  1998       Impact factor: 2.549

Review 4.  Pericardial mesothelioma.

Authors:  W T Vigneswaran; P R Stefanacci
Journal:  Curr Treat Options Oncol       Date:  2000-10

5.  Effects of natural interferon alpha, natural tumor necrosis factor alpha and their combination on human mesothelioma xenografts in nude mice.

Authors:  T Ohnuma; L Szrajer; J F Holland; M Kurimoto; J Minowada
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

6.  Blocking of ERK1 and ERK2 sensitizes human mesothelioma cells to doxorubicin.

Authors:  Arti Shukla; Jedd M Hillegass; Maximilian B MacPherson; Stacie L Beuschel; Pamela M Vacek; Harvey I Pass; Michele Carbone; Joseph R Testa; Brooke T Mossman
Journal:  Mol Cancer       Date:  2010-12-15       Impact factor: 27.401

7.  Extracellular signal regulated kinase 5 and inflammasome in progression of mesothelioma.

Authors:  Joyce K Thompson; Anurag Shukla; Alan L Leggett; Phillip B Munson; Jill M Miller; Maximilian B MacPherson; Stacie L Beuschel; Harvey I Pass; Arti Shukla
Journal:  Oncotarget       Date:  2017-12-06

8.  Extracellular signal-regulated kinase 5 and cyclic AMP response element binding protein are novel pathways inhibited by vandetanib (ZD6474) and doxorubicin in mesotheliomas.

Authors:  Mutlay Sayan; Arti Shukla; Maximilian B MacPherson; Sherrill L Macura; Jedd M Hillegass; Timothy N Perkins; Joyce K Thompson; Stacie L Beuschel; Jill M Miller; Brooke T Mossman
Journal:  Am J Respir Cell Mol Biol       Date:  2014-11       Impact factor: 6.914

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.